Steve Jenkinson is a thought leader in his field with a strong background in drug discovery and secondary pharmacology. He has managed drug discovery programmes across multiple therapeutic areas and stages, ranging from target identification to the nomination of candidates for preclinical development.

He has over 25 years leading discovery projects within GSK and Tanabe Research Laboratories and joins Metrion from Pfizer where, as Senior Director, he established, developed and led the in vitro secondary pharmacology team. Additionally, Steve was co-chair of the IQ DruSafe Secondary Pharmacology Working Group and was a member of the FDA’s HESI Pro-Arrhythmia Group.

Steve completed two Postdoctoral research fellowships, at the Scripps Institute in La Jolla and the Neurosciences Institute in San Diego, before returning to the UK to begin his drug discovery career at Pfizer, Sandwich. Steve received his undergraduate degree in Pharmacology from the University of Glasgow and PhD in Molecular Pharmacology from the University of Leicester.